JT aiming for Japan Zerenex filing following positive PhIII results
This article was originally published in Scrip
Executive Summary
Japan Tobacco (JT) is aiming to make a Japanese approval submission in its current fiscal year ending next 31 March for the ferric citrate therapy for hyperphosphataemia Zerenex (JTT-751; licensed from Keryx Biopharmaceuticals), helped by new positive results from a Phase III study.